Hyper-Inflammatory Syndrome Reported in Teens After COVID Vaccination + More By
The Defender’s COVID NewsWatch provides a roundup of the latest headlines related to the SARS CoV-2 virus, including its origins and COVID vaccines.
A Rare Hyper-Inflammatory Syndrome Has Been Reported in Teens After COVID Vaccination. Why Experts Aren’t Worried.
As federal regulators continue to investigate the COVID-19 vaccine in children under 5, a new report by the Centers for Disease Control and Prevention has identified cases of a potentially dangerous but quite rare hyper-inflammatory condition in vaccinated adolescents.
Researchers at the agency studied cases of multi-system inflammatory syndrome — an immune overreaction associated with COVID-19 infection — in vaccinated young people age 12 to 20 from Dec. 14, 2020, to Aug. 31, 2021.
They found 21 reports of MIS-C in those who received at least one dose of the COVID-19 vaccine, according to the study published Tuesday in The Lancet Child & Adolescent Health. Six showed no evidence of prior coronavirus infection, and everyone in the study received the Pfizer-BioNTech vaccine.
CDC Says Waiting Longer Between Pfizer, Moderna Doses May Reduce Rare Myocarditis Risk for Younger Men
The U.S. Centers for Disease Control and Prevention said this week that younger males should consider waiting longer between doses of Pfizer’s and Moderna’s vaccines to reduce a rare risk of heart inflammation.
The CDC said males ages 12- to 39-years-old should consider waiting eight weeks between the first and second doses of their primary COVIDvaccination series. Public health authorities in Canada found the risk of myocarditis in men ages 18- to 24-years-old was lower when they waited eight weeks for the second dose of Moderna or Pfizer.
Myocarditis is an inflammation of the heart muscle that can result in serious health problems, according to the National Heart, Lung and Blood Institute.
Very Small Blood Clot Risk After First AstraZeneca COVID Shot — UK Studies
A large study into rare blood clots linked with AstraZeneca‘s (AZN.L) COVID-19 vaccine found between just one and three cases per million, and only after the first dose, shedding fresh light on the side effects from the shot.
Researchers have sought to analyze any link between COVID-19 vaccinesand rare blood clots in the brain, arteries or veins — sometimes accompanied by low platelets, reports of which led many nations last year to pause use of the AstraZeneca shot, which was developed with Oxford University.
Sanofi and GSK Seek Approval for COVID Vaccine
The French and British drugmakers Sanofi and GSK are ready to seek approval from regulators for their COVID-19 vaccine after reporting positive results from late-stage clinical trials.
The firms are hoping to catch up with rivals after falling far behind in the race to develop COVID-19 shots. Their product was delayed by an early dosing error during trials, initially disappointing results in older people and other issues. It will be available as a two-dose vaccine and as a booster.
The companies will now file for approval from regulators, including the US Food and Drug Administration and the European Medicines Agency, while a rolling review with the UK regulator, the Medicines and Healthcare products Regulatory Agency, is already under way.
10 Cases of Serious Adverse Events Reported in Children Aged 5 to 11 After COVID Vaccine Jab: HSA
Ten cases of serious adverse events have been reported in children aged 5 to 11 who have taken their COVID-19 vaccine as of end-January, said the Health Sciences Authority (HSA) on Wednesday (Feb. 23).